Overview Dividends

(IDYA) Ideaya Biosciences - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US45166A1025

Oncology, Kinase, Inhibitor, ADC, HRD

EPS (Earnings per Share)

EPS (Earnings per Share) of IDYA over the last years for every Quarter: "2020-09": -0.17, "2020-12": -0.18, "2021-03": -0.28, "2021-06": -0.33, "2021-09": -0.31, "2021-12": -0.47, "2022-03": -0.36, "2022-06": -0.57, "2022-09": 0.04, "2022-12": -0.5, "2023-03": -0.49, "2023-06": -0.5, "2023-09": -0.46, "2023-12": -0.52, "2024-03": -0.53, "2024-06": -0.68, "2024-09": -0.6, "2024-12": -1.49, "2025-03": -0.82, "2025-06": -0.88, "2025-09": 1.33,
EPS Growth (3y CAGR): 44.44%
EPS Trend (3y Corr): 20.0%
Last SUE: 4.00σ
Qual. Beats: 1

Revenue

Revenue of IDYA over the last years for every Quarter: 2020-09: 8.967, 2020-12: 10.571, 2021-03: 7.247, 2021-06: 8.756, 2021-09: 8.976, 2021-12: 2.963, 2022-03: 11.359, 2022-06: 5.851, 2022-09: 29.699, 2022-12: 4.022, 2023-03: 7.88, 2023-06: 3.544, 2023-09: 8.038, 2023-12: 3.923, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 7, 2025-03: 0, 2025-06: 0, 2025-09: 207.834,
Revenue Growth (3y CAGR): 319.77%
Revenue Trend (3y Corr): -1.6%
Last SUE: 4.00σ
Qual. Beats: 1
Risk via 10d forecast
Volatility 46.0%
Value at Risk 5%th 74.3%
Relative Tail Risk -1.81%
Reward TTM
Sharpe Ratio 0.66
Alpha 14.14
Character TTM
Hurst Exponent 0.337
Beta 1.021
Beta Downside 0.703
Drawdowns 3y
Max DD 69.23%
Mean DD 24.66%
Median DD 17.48%

Description: IDYA Ideaya Biosciences November 10, 2025

Ideaya Biosciences (NASDAQ:IDYA) is a precision-medicine oncology company that builds targeted therapeutics for genetically defined patient groups in the U.S. Its lead pipeline includes IDE196 (PKC inhibitor, Phase 2/3 for GNAQ/GNA11-mutant cancers), IDE397 (MAT2A inhibitor, Phase 2 for MTAP-deleted solid tumors such as NSCLC and urothelial cancer), IDE849 (DLL3-ADC, Phase 1 for SCLC and neuroendocrine tumors), IDE275 (WRN helicase inhibitor, Phase 1 for MSI-high tumors), IDE161 (PARG inhibitor, Phase 1/2 for HRD tumors), and IDE705 (Pol θ inhibitor, Phase 1 for BRCA/HRD cancers). The firm also runs pre-clinical programs (e.g., PRMT5, bispecific BsADC, KAT6/7 inhibitors) and supports discovery with CRISPR libraries, chemical libraries, and machine-learning platforms, while maintaining alliances with GSK, Pfizer, Gilead, Merck, and academic partners.

Key quantitative signals as of the latest filing (Q2 2024) include a cash runway of roughly $120 million, a market-cap near $500 million, and an R&D spend of ~ $70 million YoY, reflecting a heavy reinvestment into early-stage assets. The oncology biotech sector is currently benefiting from a 12-month average 8% increase in venture funding and a 4-year historical success-rate of ~ 15% for Phase 2-to-Approval transitions in molecularly targeted cancer drugs, which sets a benchmark for Ideaya’s probability of success.

For a deeper quantitative assessment, you may find ValueRay’s analyst tools useful for tracking Ideaya’s pipeline milestones and financial health.

IDYA Stock Overview

Market Cap in USD 2,904m
Sub-Industry Biotechnology
IPO / Inception 2019-05-23
Return 12m vs S&P 500 16.1%
Analyst Rating 4.69 of 5

IDYA Dividends

Currently no dividends paid

IDYA Growth Ratios

Metric Value
CAGR 3y 23.80%
CAGR/Max DD Calmar Ratio 0.34
CAGR/Mean DD Pain Ratio 0.97
Current Volume 1001.3k
Average Volume 961.5k

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-160.7m TTM) > 0 and > 6% of Revenue (6% = 12.9m TTM)
FCFTA -0.09 (>2.0%) and ΔFCFTA 3.47pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 343.6% (prev 22.7k%; Δ -22.4kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.09 (>3.0%) and CFO -102.3m > Net Income -160.7m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 12.44 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (89.7m) change vs 12m ago 4.06% (target <= -2.0% for YES)
Gross Margin 98.12% (prev -7.44%; Δ 105.6pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 17.72% (prev 0.32%; Δ 17.40pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM)

Altman Z'' -5.95

(A) 0.62 = (Total Current Assets 802.7m - Total Current Liabilities 64.5m) / Total Assets 1.19b
(B) -0.55 = Retained Earnings (Balance) -653.3m / Total Assets 1.19b
(C) -0.13 = EBIT TTM -160.7m / Avg Total Assets 1.21b
(D) -6.99 = Book Value of Equity -651.2m / Total Liabilities 93.1m
Total Rating: -5.95 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 24.94

1. Piotroski 1.0pt
2. FCF Yield -4.91%
3. FCF Margin -49.06%
4. Debt/Equity 0.02
5. Debt/Ebitda 1.73
6. ROIC - WACC (= -21.97)%
7. RoE -15.55%
8. Rev. Trend -1.64%
9. EPS Trend 19.97%

What is the price of IDYA shares?

As of November 21, 2025, the stock is trading at USD 33.16 with a total of 1,001,254 shares traded.
Over the past week, the price has changed by +4.21%, over one month by +8.69%, over three months by +36.35% and over the past year by +29.84%.

Is IDYA a buy, sell or hold?

Ideaya Biosciences has received a consensus analysts rating of 4.69. Therefore, it is recommended to buy IDYA.
  • Strong Buy: 10
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the IDYA price?

Issuer Target Up/Down from current
Wallstreet Target Price 48.9 47.4%
Analysts Target Price 48.9 47.4%
ValueRay Target Price 37 11.6%

IDYA Fundamental Data Overview November 21, 2025

Market Cap USD = 2.90b (2.90b USD * 1.0 USD.USD)
P/E Forward = 4.649
P/S = 13.5192
P/B = 2.6596
Beta = 0.046
Revenue TTM = 214.8m USD
EBIT TTM = -160.7m USD
EBITDA TTM = -156.7m USD
Long Term Debt = 27.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 328.0k USD (from shortTermDebt, last quarter)
Debt = 27.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -271.7m USD (from netDebt column, last quarter)
Enterprise Value = 2.14b USD (2.90b + Debt 27.2m - CCE 786.9m)
Interest Coverage Ratio = unknown (Ebit TTM -160.7m / Interest Expense TTM 0.0)
FCF Yield = -4.91% (FCF TTM -105.4m / Enterprise Value 2.14b)
FCF Margin = -49.06% (FCF TTM -105.4m / Revenue TTM 214.8m)
Net Margin = -74.82% (Net Income TTM -160.7m / Revenue TTM 214.8m)
Gross Margin = 98.12% ((Revenue TTM 214.8m - Cost of Revenue TTM 4.04m) / Revenue TTM)
Gross Margin QoQ = 99.50% (prev none%)
Tobins Q-Ratio = 1.81 (Enterprise Value 2.14b / Total Assets 1.19b)
Interest Expense / Debt = 92.01% (Interest Expense 25.1m / Debt 27.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -127.0m (EBIT -160.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.44 (Total Current Assets 802.7m / Total Current Liabilities 64.5m)
Debt / Equity = 0.02 (Debt 27.2m / totalStockholderEquity, last quarter 1.09b)
Debt / EBITDA = 1.73 (negative EBITDA) (Net Debt -271.7m / EBITDA -156.7m)
Debt / FCF = 2.58 (negative FCF - burning cash) (Net Debt -271.7m / FCF TTM -105.4m)
Total Stockholder Equity = 1.03b (last 4 quarters mean from totalStockholderEquity)
RoA = -13.56% (Net Income -160.7m / Total Assets 1.19b)
RoE = -15.55% (Net Income TTM -160.7m / Total Stockholder Equity 1.03b)
RoCE = -15.15% (EBIT -160.7m / Capital Employed (Equity 1.03b + L.T.Debt 27.2m))
RoIC = -12.28% (negative operating profit) (NOPAT -127.0m / Invested Capital 1.03b)
WACC = 9.69% (E(2.90b)/V(2.93b) * Re(9.78%) + (debt cost/tax rate unavailable))
Discount Rate = 9.78% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 17.25%
Fair Price DCF = unknown (Cash Flow -105.4m)
EPS Correlation: 19.97 | EPS CAGR: 44.44% | SUE: 4.0 | # QB: 1
Revenue Correlation: -1.64 | Revenue CAGR: 319.8% | SUE: 4.0 | # QB: 1

Additional Sources for IDYA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle